These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 37779203)
1. Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021. Martinez A; Khan T; Dylla DE; Marcinak J; Collins M; Saget B; Conway B Harm Reduct J; 2023 Oct; 20(1):142. PubMed ID: 37779203 [TBL] [Abstract][Full Text] [Related]
2. Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients. Ing Lorenzini K; Girardin F Liver Int; 2020 Jan; 40(1):32-44. PubMed ID: 31654604 [TBL] [Abstract][Full Text] [Related]
3. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251 [TBL] [Abstract][Full Text] [Related]
4. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals. Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N; Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study. Heo J; Kim YJ; Lee SW; Lee YJ; Yoon KT; Byun KS; Jung YJ; Tak WY; Jeong SH; Kwon KM; Suri V; Wu P; Jang BK; Lee BS; Cho JY; Jang JW; Yang SH; Paik SW; Kim HJ; Kwon JH; Park NH; Kim JH; Kim IH; Ahn SH; Lim YS Korean J Intern Med; 2023 Jul; 38(4):504-513. PubMed ID: 37424500 [TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection. Indolfi G; Kelly D; Nebbia G; Iorio R; Mania A; Giacomet V; Szenborn L; Shao J; Sang Yue M; Hsueh CH; Parhy B; Kersey K; Mangia A; Pawlowska M; Bansal S Hepatology; 2022 Aug; 76(2):445-455. PubMed ID: 35112372 [TBL] [Abstract][Full Text] [Related]
7. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949 [TBL] [Abstract][Full Text] [Related]
8. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Roncero C; Villegas JL; Martínez-Rebollar M; Buti M Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279 [TBL] [Abstract][Full Text] [Related]
14. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. Gao LH; Nie QH; Zhao XT Int J Gen Med; 2021; 14():289-301. PubMed ID: 33536776 [TBL] [Abstract][Full Text] [Related]
15. Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase. Hayes KN; Burkard T; Weiler S; Tadrous M; Burden AM Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1017-e1021. PubMed ID: 33883523 [TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. Bourlière M; Gordon SC; Flamm SL; Cooper CL; Ramji A; Tong M; Ravendhran N; Vierling JM; Tran TT; Pianko S; Bansal MB; de Lédinghen V; Hyland RH; Stamm LM; Dvory-Sobol H; Svarovskaia E; Zhang J; Huang KC; Subramanian GM; Brainard DM; McHutchison JG; Verna EC; Buggisch P; Landis CS; Younes ZH; Curry MP; Strasser SI; Schiff ER; Reddy KR; Manns MP; Kowdley KV; Zeuzem S; N Engl J Med; 2017 Jun; 376(22):2134-2146. PubMed ID: 28564569 [TBL] [Abstract][Full Text] [Related]
17. Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection. Sicras-Mainar A; Morillo-Verdugo R Adicciones; 2022 Nov; 34(4):279-284. PubMed ID: 33338248 [TBL] [Abstract][Full Text] [Related]
18. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703 [TBL] [Abstract][Full Text] [Related]
19. Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy. Gheorghe L; Preda C; Trifan A; Manuc M; Stanciu C; Istratescu D; Popescu CP; Diculescu MM; Tieranu CG; Manuc T; Stroie TG; Iacob SM; Iliescu L J Gastrointestin Liver Dis; 2022 Dec; 31(4):437-443. PubMed ID: 36535062 [TBL] [Abstract][Full Text] [Related]
20. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5. Liu CH; Kao JH Hepatol Int; 2022 Oct; 16(5):1001-1019. PubMed ID: 35876967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]